Irene M. Lako
University of Groningen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Irene M. Lako.
Journal of Affective Disorders | 2012
Irene M. Lako; Richard Bruggeman; Durk Wiersma; Robert A. Schoevers; Cees J. Slooff; Katja Taxis
BACKGROUND Depressive symptoms require accurate recognition and monitoring in clinical practice of patients with schizophrenia. Depression instruments developed for use in depressed patients may not discriminate depressive symptoms from negative psychotic symptoms. OBJECTIVE We reviewed depression instruments on their reliability and validity in patients with schizophrenia. METHODOLOGY A systematic literature search was carried out in three electronic databases. Psychometric properties were extracted for those instruments of which reliability, divergent, concurrent and predictive validity were reported in one or more publications. RESULTS Forty-eight publications described the reliability and validity of six depression instruments in patients with schizophrenia. The only self-report was the Beck Depression Inventory (BDI). The Brief Psychiatric Rating Scale-Depression subscale (BPRS-D), Positive and Negative Syndrome Scale-Depression subscale (PANSS-D), Hamilton Rating Scale for Depression (HAMD), Montgomery Asberg Depression Rating Scale (MADRS) and Calgary Depression Scale for Schizophrenia (CDSS) were clinician rated. All instruments were reliable for the measurement of depressive symptoms in patients with schizophrenia. The CDSS most accurately differentiated depressive symptoms from other symptoms of schizophrenia (divergent validity), correlated well with other depression instruments (concurrent validity), and was least likely to miss cases of depression or misdiagnose depression (predictive validity). CONCLUSIONS We would recommend to use the CDSS for the measurement of depressive symptoms in research and in daily clinical practice of patients with schizophrenia. A valid self-report instrument is to be developed for the use in clinical practice.
Journal of Clinical Psychopharmacology | 2013
Irene M. Lako; Edith J. Liemburg; Edwin R. van den Heuvel; Richard Bruggeman; Katja Taxis
Rationale: Dose equivalents based on dopamine D2 receptor occupancy can be used to compare antipsychotics on D2 receptor-mediated (adverse) effects such as extrapyramidal symptoms and altered emotional experiences. Previous meta-analyses modeling the dose-occupancy relationship hardly addressed potential heterogeneity of the imaging data. Objectives: To model the relationship between dose and D2 receptor occupancy for a series of frequently prescribed antipsychotics while addressing the potential heterogeneity of the imaging data. Methods: We conducted a meta-analysis on published D2 receptor occupancy data (positron emission tomography and single-photon emission computed tomography) in patients with schizophrenia treated with antipsychotics. A nonlinear mixed effects model estimated the median D2 receptor occupancy for a given antipsychotic dose. Heterogeneity between studies was investigated by incorporating study as a random effect in the model, in addition to patient- and study-specific explanatory variables. Results: Included were 51 studies, describing 606 patients (mean T SD age, 32.2 T10.8 years; 25.7% female). The models described the doseoccupancy relationship with narrow confidence bands around the therapeutic dose range. Maximum occupancy (95% confidence interval [CI]) was estimated for haloperidol (91.9%; 95% CI, 86.1Y97.8), risperidone (92.4%; 95% CI, 81.8Y100), olanzapine (96.5%; 95% CI, 85.8Y100), clozapine (61.7%; 95% CI, 49.2Y74.2), quetiapine (49.1%; 95% CI, 18.7Y79.6), aripiprazole (86.9%; 95% CI, 78.2Y95.7), ziprasidone (82.9%; 95% CI, 44.9Y100), and amisulpride (85.0%; 95% CI, 68.5Y100). Interindividual differences explained most of the variability in occupancy values, besides significant heterogeneity between studies. Conclusions: Dose-occupancy functions estimated the median level of dopamine D2 receptor occupancy for 8 frequently prescribed antipsychotics in patients with schizophrenia. These dose equivalents can be
BMC Psychiatry | 2014
Irene M. Lako; Johanna T. W. Wigman; Rianne M. C. Klaassen; Cees J. Slooff; Katja Taxis; Agna A. Bartels-Velthuis
BackgroundSelf-report instruments for the assessment of depressive symptoms in patients with psychotic disorders are scarce. The Quick Inventory of Depressive Symptoms (QIDS-SR16) may be a useful self-report instrument, but has received little attention in this field. This paper aimed to test the psychometric properties of the QIDS-SR16 questionnaire in patients with a psychotic disorder.MethodsPatients diagnosed with a psychotic disorder from health care institutions in The Netherlands were included in the study. Depressive symptoms were assessed with the QIDS-SR16 and the Calgary Depression Scale for Schizophrenia (CDSS). Psychotic symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS) and extrapyramidal symptoms (EPS) with three EPS rating scales. Spearman’s correlation coefficients were used to compare the total score of the QIDS-SR16 with the total scores of the CDSS, PANSS-subscales and EPS rating scales.ResultsIn a sample of 621 patients with psychotic disorders, the QIDS-SR16 showed good internal consistency (α = 0.87). The QIDS-SR16 correlated moderately with the CDSS (r = 0.44) and the PANSS subscale for emotional distress (r = 0.47). The QIDS-SR16 showed weak correlation with the PANSS subscale for negative symptoms (r = 0.28) and minimal correlation with EPS rating scales (r = 0.09-0.16).ConclusionsThe QIDS-SR16 may reliably assess depressive symptoms in patients with psychotic disorders, but its concurrent validity with the CDSS was rather poor in this population. We would recommend developing a new self-report questionnaire for the assessment of depressive symptoms in patients with psychotic disorders.
Journal of Neuroscience Methods | 2013
Cathalijn H.C. Leenaars; Carlos E.N. Girardi; Ruud N.J.M.A. Joosten; Irene M. Lako; Emma Ruimschotel; Maaike A.J. Hanegraaf; Maurice Dematteis; Matthijs G.P. Feenstra; Eus J. W. Van Someren
The relationship between learning and sleep is multifaceted; learning influences subsequent sleep characteristics, which may in turn influence subsequent memory. Studies in humans indicate that sleep may not only prevent degradation of acquired memories, but even enhance performance without further practice. In a rodent instrumental learning task, individual differences occur in how fast rats learn to associate lever pressing with food reward. Rats habitually sleep between learning sessions, and may differ in this respect. The current study assessed if the instrumental leaning paradigm could serve as a model to study sleep-dependent memory enhancement. Male Wistar rats performed 2 sessions of instrumental learning per day for 1-3 days. Electroencephalography was recorded both before and after the sessions. Sleep deprivation (3 h) was applied between the first and second session in a subgroup of rats. Measurements comprised the number of lever presses in each session, slow wave sleep (SWS) duration, Rapid Eye Movement Sleep (REMS) duration and sleep spindles. Baseline sleep parameters were similar for fast and slow learning rats. Task-exposure increased REMS-duration. The increase in REMS-duration was observed specifically after sessions in which learning occurred, but not after a later session. Sleep deprivation during the 3h period between the initial two sessions interfered with performance enhancement, but did not prevent this in all rats. Our considered movement control protocol induced partial sleep deprivation and also interfered with performance enhancement. The classic instrumental learning task provides a practical model for animal studies on sleep-dependent memory enhancement.
Schizophrenia Research | 2013
Irene M. Lako; Richard Bruggeman; Edith J. Liemburg; Edwin R. van den Heuvel; Cees J. Slooff; Durk Wiersma; Katja Taxis
Psychiatry Research-neuroimaging | 2016
Irene M. Lako; Katja Taxis; Edwin R. van den Heuvel; Cathalijn H.C. Leenaars; Huibert Burger; Durk Wiersma; Cees J. Slooff; Richard Bruggeman
Schizophrenia Research | 2012
Irene M. Lako; Edith J. Liemburg; Edwin R. van den Heuvel; H. Knegtering; Cees Slooff; Durk Wiersma; Richard Bruggeman; Katja Taxis
/data/revues/09249338/unassign/S0924933810002233/ | 2012
Irene M. Lako; Katja Taxis; Richard Bruggeman; H. Knegtering; H. Burger; D. Wiersma; Cj Slooff
Pharmacoepidemiology and Drug Safety | 2011
Katja Taxis; Irene M. Lako; Huibert Burger; Rikus Knegtering; Ha Wolters; Durk Wiersma; Richard Bruggeman
Pharmacoepidemiology and Drug Safety | 2011
Katja Taxis; Irene M. Lako; Huib Burger; Hendrikus Knegtering; Ha Wolters; Durk Wiersma; Richard Bruggeman